Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy
JNCI: Journal of the National Cancer Institute · 2024
DOI: 10.1093/jnci/djae152 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Sean J Judge und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Watchful Waiting, Magnetic Resonance Imaging. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, John and Michelle Martello Research Fund, NCI.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Neoadjuvant therapy leads to a clinical complete response in a considerable proportion of patients with locally advanced rectal cancer, allowing for possible nonoperative management. The presence of mucin on magnetic resonance imaging (MRI) after neoadjuvant therapy leads to uncertainty about residual disease and appropriateness of a watch-and-wait strategy in patients with no evidence of disease on proctoscopy (endoscopic clinical complete response).
Methods
MRI reports for locally advanced rectal cancer patients seen between July 2016 and January 2020 at Memorial Sloan Kettering Cancer Center were queried for presence of mucin in the tumor bed on MRI following neoadjuvant therapy. Clinicodemographic, pathologic, and outcome data were compiled and analyzed.
Results
Of 71 patients with mucin on posttreatment MRI, 20 had a clinical complete response, and 51 had abnormalities on endoscopy and/or physical exam. One patient with a clinical complete response opted out of watch-and-wait; thus, 19 (27%) patients entered watch-and-wait, and 52 (73%) patients were planned for surgery (non–watch-and-wait). Of the 19 watch-and-wait patients, 15 (79%) have had no local regrowth with median follow-up of 50 months (range = 29-76 months), while 4 (21%) experienced regrowth between 9 and 29 months after neoadjuvant therapy. Of the 52 patients who were planned to have surgery (non–watch-and-wait), 49 underwent resection while 3 developed metastatic disease that precluded curative-intent surgery. Of the 49 patients who underwent surgery, 5 (10%) had a pathologic complete response (including the patient with an endoscopic clinical complete response).
Conclusions
The presence of mucin after neoadjuvant therapy for locally advanced rectal cancer does not preclude watch-and-wait management in otherwise appropriate candidates who achieve an endoscopic clinical complete response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
ORCID-Profile: Andrea Cercek, Paul Romesser, Jinru Shia, Emmanouil Pappou, Martin R Weiser
Förderung
- NCI NIH HHS
- John and Michelle Martello Research Fund
- NCI
Zitieren
APA
Judge, S. J., Malekzadeh, P., Corines, M. J., Gollub, M. J., Horvat, N., Gonen, M., Saltz, L., Cercek, A., Romesser, P., Crane, C., Shia, J., Wei, I., Widmar, M., Pappou, E., Nash, G. M., Smith, J. J., Paty, P. B., Garcia-Aguilar, J., & Weiser, M. R. (2024). Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae152
Vancouver
Judge SJ, Malekzadeh P, Corines MJ, Gollub MJ, Horvat N, Gonen M, et al. Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae152
BibTeX
@article{Judge2024,
author = {Judge, Sean J and Malekzadeh, Parisa and Corines, Marina J and Gollub, Marc J and Horvat, Natally and Gonen, Mithat and Saltz, Leonard and Cercek, Andrea and Romesser, Paul and Crane, Christopher and Shia, Jinru and Wei, Iris and Widmar, Maria and Pappou, Emmanouil and Nash, Garrett M and Smith, J Joshua and Paty, Philip B and Garcia-Aguilar, Julio and Weiser, Martin R},
title = {Watch and wait in rectal cancer patients with residual mucin on magnetic resonance imaging following neoadjuvant therapy},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2024},
doi = {10.1093/jnci/djae152}
}
EUVIMED